View in EDS

VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.

Saved in:
Bibliographic Details
Title: VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.
Authors: Allen V; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, K1H 8M5, ON, Canada., Coulombe J; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada., Zhao H; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada., Kreps LM; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, K1H 8M5, ON, Canada., Cook DP; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada., Pryce B; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada., Clemons M; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada., Vanderhyden BC; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada., Gray DA; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, K1H 8M5, ON, Canada., Addison CL; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada. caddison@ohri.ca.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, K1H 8M5, ON, Canada. caddison@ohri.ca.; Department of Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada. caddison@ohri.ca.
Source: British journal of cancer [Br J Cancer] 2022 Jul; Vol. 127 (1), pp. 56-68. Date of Electronic Publication: 2022 Mar 22.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35318435
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Allen+V%22">Allen V</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, K1H 8M5, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Coulombe+J%22">Coulombe J</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Zhao+H%22">Zhao H</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Kreps+LM%22">Kreps LM</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, K1H 8M5, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Cook+DP%22">Cook DP</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Pryce+B%22">Pryce B</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Clemons+M%22">Clemons M</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Vanderhyden+BC%22">Vanderhyden BC</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Gray+DA%22">Gray DA</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, K1H 8M5, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Addison+CL%22">Addison CL</searchLink>; Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, K1H 8L6, ON, Canada. caddison@ohri.ca.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, K1H 8M5, ON, Canada. caddison@ohri.ca.; Department of Medicine, University of Ottawa, Ottawa, K1H 8M5, ON, Canada. caddison@ohri.ca.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370635%22">British journal of cancer</searchLink> [Br J Cancer] 2022 Jul; Vol. 127 (1), pp. 56-68. <i>Date of Electronic Publication: </i>2022 Mar 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group+on+behalf+of+Cancer+Research+UK%22">Nature Publishing Group on behalf of Cancer Research UK </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0370635 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-1827 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200070920%22">00070920 </searchLink><i>NLM ISO Abbreviation: </i>Br J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35318435
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41416-022-01778-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 56
    Titles:
      – TitleFull: VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Allen V
      – PersonEntity:
          Name:
            NameFull: Coulombe J
      – PersonEntity:
          Name:
            NameFull: Zhao H
      – PersonEntity:
          Name:
            NameFull: Kreps LM
      – PersonEntity:
          Name:
            NameFull: Cook DP
      – PersonEntity:
          Name:
            NameFull: Pryce B
      – PersonEntity:
          Name:
            NameFull: Clemons M
      – PersonEntity:
          Name:
            NameFull: Vanderhyden BC
      – PersonEntity:
          Name:
            NameFull: Gray DA
      – PersonEntity:
          Name:
            NameFull: Addison CL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2022 Jul
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1532-1827
          Numbering:
            – Type: volume
              Value: 127
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: British journal of cancer
              Type: main
ResultId 1